内容紹介
Second-Line Chemotherapy for Advanced Pancreatic Cancer
Summary
Many investigators have attempted to reach a consensus, though with limited evidence available, on second-line chemotherapy for advanced pancreatic cancer. Specifically, treatment consists of gemcitabine-based regimens and 5-FU-based regimens. The regimen that is not used for first-line chemotherapy will be used as second-line chemotherapy. In Japan, S-1 is frequently used in 5-FU-based regimens. When the FOLFIRINOX regimen is used as first-line chemotherapy, gemcitabine is recommended as second-line chemotherapy. On the other hand, when nab-PTX/gemcitabine is used as first-line chemotherapy, S-1 is recommended as second-line chemotherapy.
要旨
切除不能進行膵癌の二次化学療法の有用性についてエビデンスは十分ではないものの,ほぼコンセンサスとなっている。治療内容をgemcitabine-based regimenと5-FU-based regimenに分けて,一次治療に用いられていないregimenを二次治療として選択することになる。本邦では5-FU-based regimenとしてはS-1が頻用されている。現在,注目されているFOLFIRINOX療法が一次治療であれば二次治療はgemcitabineが推奨され,nab-paclitaxel+gemcitabine併用療法が一次治療であればS-1が推奨される。
目次
Summary
Many investigators have attempted to reach a consensus, though with limited evidence available, on second-line chemotherapy for advanced pancreatic cancer. Specifically, treatment consists of gemcitabine-based regimens and 5-FU-based regimens. The regimen that is not used for first-line chemotherapy will be used as second-line chemotherapy. In Japan, S-1 is frequently used in 5-FU-based regimens. When the FOLFIRINOX regimen is used as first-line chemotherapy, gemcitabine is recommended as second-line chemotherapy. On the other hand, when nab-PTX/gemcitabine is used as first-line chemotherapy, S-1 is recommended as second-line chemotherapy.
要旨
切除不能進行膵癌の二次化学療法の有用性についてエビデンスは十分ではないものの,ほぼコンセンサスとなっている。治療内容をgemcitabine-based regimenと5-FU-based regimenに分けて,一次治療に用いられていないregimenを二次治療として選択することになる。本邦では5-FU-based regimenとしてはS-1が頻用されている。現在,注目されているFOLFIRINOX療法が一次治療であれば二次治療はgemcitabineが推奨され,nab-paclitaxel+gemcitabine併用療法が一次治療であればS-1が推奨される。